1228 Real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab containing regimen in first-line, or sequentially in first- and second-line, from a US private payer perspective. (September 2015) - Johnston, S.; Wilson, K.; Riehle, E.; Varker, H.; Juneau, P.; Sommer, N.; Ogale, S.